Wedbush Securities Inc Biomarin Pharmaceutical Inc Transaction History

Wedbush Securities Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 21, 2022	SELL	$71.48 - $86.85 $27,591 - $33,524	-386 Reduced 11.47%	2,979 $246,000
Q1 2022 Apr 19, 2022	BUY	$74.28 - $92.69 $41,819 - $52,184	563 Added 20.09%	3,365 $259,000
Q4 2021 Jan 13, 2022	BUY	$71.72 - $91.47 $200,959 - $256,298	2,802 New	2,802 $247,000
Q3 2020 Oct 20, 2020	SELL	$71.87 - $131.03 $124,910 - $227,730	-1,738 Closed	0 $0
Q2 2020 Jul 16, 2020	SELL	$79.55 - $124.22 $110,415 - $172,417	-1,388 Reduced 44.4%	1,738 $214,000
Q1 2020 Apr 17, 2020	BUY	$71.37 - $96.85 $38,182 - $51,814	535 Added 20.65%	3,126 $264,000
Q4 2019 Jan 16, 2020	BUY	$64.27 - $86.37 $166,523 - $223,784	2,591 New	2,591 $219,000
Q4 2018 Jan 31, 2019	SELL	$80.14 - $106.07 $216,858 - $287,025	-2,706 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $6,950 - $7,823	-74 Reduced 2.66%	2,706 $262,000
Q2 2018 Aug 03, 2018	BUY	$76.01 - $99.03 $211,307 - $275,303	2,780 New	2,780 $262,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.